Professional Documents
Culture Documents
1
7
8
w
e
e
k
s
5
,
1
0
,
1
5
m
g
/
d
a
y
a
n
d
p
l
a
c
e
b
o
I
m
p
r
o
v
e
m
e
n
t
s
i
n
A
B
C
-
I
s
u
b
s
c
a
l
e
s
c
o
r
e
(
a
r
i
p
i
p
r
a
z
o
l
e
1
2
.
9
v
s
.
p
l
a
c
e
b
o
-
5
.
0
;
P
,
0
.
0
0
1
)
a
n
d
C
G
I
-
I
s
c
o
r
e
(
2
.
2
v
s
.
3
.
3
;
P
,
0
.
0
0
1
)
.
C
l
i
n
i
c
a
l
l
y
s
i
g
n
i
f
c
a
n
t
r
e
s
i
d
u
a
l
s
y
m
p
t
o
m
s
m
a
y
s
t
i
l
l
p
e
r
s
i
s
t
f
o
r
s
o
m
e
p
a
t
i
e
n
t
s
.
N
o
s
e
r
i
o
u
s
a
d
v
e
r
s
e
e
v
e
n
t
s
.
D
i
s
c
o
n
t
i
n
u
a
t
i
o
n
d
u
e
t
o
a
d
v
e
r
s
e
e
v
e
n
t
s
:
A
P
Z
;
1
0
.
6
%
,
p
l
a
c
e
b
o
;
5
.
9
%
.
E
P
S
:
A
P
Z
;
1
4
.
9
%
,
p
l
a
c
e
b
o
;
8
.
0
%
.
M
e
a
n
w
e
i
g
h
t
g
a
i
n
:
A
P
Z
;
2
.
0
k
g
,
p
l
a
c
e
b
o
;
0
.
8
k
g
.
A
r
i
p
i
p
r
a
z
o
l
e
M
a
r
c
u
s
e
t
a
l
.
.
(
2
0
0
9
)
R
a
n
d
o
m
i
z
e
d
,
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
,
p
a
r
a
l
l
e
l
-
g
r
o
u
p
s
t
u
d
y
A
u
t
i
s
t
i
c
d
i
s
o
r
d
e
r
w
h
o
h
a
d
t
a
n
t
r
u
m
s
,
a
g
g
r
e
s
s
i
o
n
,
o
r
s
e
l
f
-
i
n
j
u
r
y
(
2
1
8
)
6
1
7
8
w
e
e
k
s
5
,
1
0
,
o
r
1
5
m
g
/
d
a
y
a
n
d
p
l
a
c
e
b
o
I
m
p
r
o
v
e
m
e
n
t
s
i
n
A
B
C
-
I
s
u
b
s
c
a
l
e
s
c
o
r
e
s
(
a
r
i
p
i
p
r
a
z
o
l
e
5
m
g
/
d
a
y
,
-
1
2
.
4
;
1
0
m
g
/
d
a
y
,
-
1
3
.
2
,
1
5
m
g
/
d
a
y
-
1
4
.
4
v
s
.
p
l
a
c
e
b
o
,
-
8
.
4
;
a
l
l
P
,
0
.
0
5
)
a
n
d
C
G
I
-
I
s
c
o
r
e
(
P
l
a
c
e
b
o
3
.
3
,
a
r
i
p
i
p
r
a
z
o
l
e
5
m
g
/
d
a
y
2
.
6
,
P
=
0
.
0
0
3
;
1
0
m
g
/
d
a
y
2
.
5
,
P
,
0
.
0
0
1
;
1
5
m
g
/
d
a
y
2
.
5
,
P
,
0
.
0
0
1
)
.
S
e
d
a
t
i
o
n
(
2
3
.
6
%
)
.
S
e
r
i
o
u
s
a
d
v
e
r
s
e
e
v
e
n
t
s
:
p
r
e
s
y
n
c
o
p
e
(
0
.
4
6
%
)
,
a
g
g
r
e
s
-
s
i
o
n
(
0
.
4
6
%
)
.
A
r
i
p
i
p
r
a
z
o
l
e
F
i
n
d
l
i
n
g
e
t
a
l
(
2
0
1
4
)
M
u
l
t
i
c
e
n
t
e
r
,
d
o
u
b
l
e
-
b
l
i
n
d
,
r
a
n
d
o
m
i
z
e
d
,
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
,
r
e
l
a
p
s
e
-
p
r
e
v
e
n
t
i
o
n
t
r
i
a
l
A
u
t
i
s
t
i
c
d
i
s
o
r
d
e
r
(
8
5
)
6
1
7
1
3
2
6
w
e
e
k
s
i
n
p
h
a
s
e
1
(
s
i
n
g
l
e
b
l
i
n
d
)
a
n
d
1
2
w
e
e
k
s
i
n
p
h
a
s
e
2
(
d
o
u
b
l
e
-
b
l
i
n
d
,
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
)
2
1
5
m
g
/
d
a
y
a
n
d
p
l
a
c
e
b
o
N
o
d
i
f
f
e
r
e
n
c
e
i
n
t
i
m
e
t
o
r
e
l
a
p
s
e
b
e
t
w
e
e
n
a
r
i
p
i
p
r
a
z
o
l
e
a
n
d
p
l
a
c
e
b
o
(
P
=
.
0
9
7
)
.
K
a
p
l
a
n
-
M
e
i
e
r
r
e
l
a
p
s
e
r
a
t
e
s
a
t
w
e
e
k
1
6
:
3
5
%
f
o
r
a
r
i
p
i
p
r
a
z
o
l
e
,
5
2
%
f
o
r
p
l
a
c
e
b
o
(
h
a
z
a
r
d
r
a
t
i
o
=
0
.
5
7
;
n
u
m
b
e
r
n
e
e
d
e
d
t
o
t
r
e
a
t
=
6
)
.
P
h
a
s
e
1
:
w
e
i
g
h
t
i
n
c
r
e
a
s
e
(
2
5
.
2
%
)
,
s
o
m
n
o
l
e
n
c
e
(
1
4
.
8
%
)
,
v
o
m
i
t
i
n
g
(
1
4
.
2
%
)
.
P
h
a
s
e
2
:
(
a
r
i
p
i
p
r
a
z
o
l
e
v
s
.
p
l
a
c
e
b
o
)
,
u
p
p
e
r
r
e
s
p
i
r
a
t
o
r
y
t
r
a
c
t
i
n
f
e
c
t
i
o
n
(
1
0
.
3
%
v
s
.
2
.
3
%
)
,
c
o
n
s
t
i
p
a
t
i
o
n
(
5
.
1
%
v
s
.
0
%
)
,
m
o
v
e
m
e
n
t
d
i
s
o
r
d
e
r
(
5
.
1
%
v
s
.
0
%
)
.
R
i
s
p
e
r
i
d
o
n
e
M
c
C
r
a
c
k
e
n
e
t
a
l
(
R
e
s
e
a
r
c
h
U
n
i
t
s
o
n
P
e
d
i
a
t
r
i
c
P
s
y
c
h
o
p
h
a
r
m
a
c
o
l
o
g
y
A
u
t
i
s
m
,
N
e
t
w
o
r
k
)
(
2
0
0
2
)
M
u
l
t
i
s
i
t
e
,
r
a
n
d
o
m
i
z
e
d
,
d
o
u
b
l
e
-
b
l
i
n
d
t
r
i
a
l
A
u
t
i
s
t
i
c
d
i
s
o
r
d
e
r
(
1
0
1
)
5
1
7
8
w
e
e
k
s
0
.
5
3
.
5
m
g
/
d
a
y
R
e
s
p
o
n
d
e
r
s
(
2
5
%
d
e
c
r
e
a
s
e
i
n
t
h
e
I
r
r
i
t
a
b
i
l
i
t
y
s
c
o
r
e
a
n
d
a
r
a
t
i
n
g
o
f
m
u
c
h
i
m
p
r
o
v
e
d
o
r
v
e
r
y
m
u
c
h
i
m
p
r
o
v
e
d
o
n
t
h
e
C
G
I
-
I
s
c
a
l
e
)
(
r
i
s
p
e
r
i
d
o
n
e
6
9
%
v
s
.
p
l
a
c
e
b
o
1
2
%
;
P
,
0
.
0
0
1
)
A
v
e
r
a
g
e
w
e
i
g
h
t
g
a
i
n
o
f
2
.
7
2
.
9
k
g
,
(
v
s
.
P
l
a
c
e
b
o
,
0
.
8
2
.
2
;
P
,
0
.
0
0
1
)
i
n
c
r
e
a
s
e
d
a
p
p
e
t
i
t
e
,
f
a
t
i
g
u
e
,
d
r
o
w
s
i
-
n
e
s
s
,
d
i
z
z
i
n
e
s
s
,
d
r
o
o
l
i
n
g
R
i
s
p
e
r
i
d
o
n
e
P
a
n
d
i
n
a
e
t
a
l
.
(
2
0
0
7
)
D
o
u
b
l
e
-
b
l
i
n
d
,
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
t
r
i
a
l
A
u
t
i
s
m
(
5
5
)
5
1
2
8
w
e
e
k
s
1
.
3
7
m
g
/
d
a
y
I
m
p
r
o
v
e
m
e
n
t
s
i
n
A
B
C
-
I
(
r
i
s
p
e
r
i
d
o
n
e
,
-
1
3
.
4
1
.
5
v
s
p
l
a
c
e
b
o
,
-
7
.
2
1
.
5
;
P
,
0
.
0
5
)
S
o
m
n
o
l
e
n
c
e
(
7
4
%
)
Pharmacotherapy for the treatment of irritability in autistic children
23 CLINICAL MEDICINE INSIGHTS: PEDIATRICS 2014:8
R
i
s
p
e
r
i
d
o
n
e
S
h
e
a
e
t
a
l
.
(
2
0
0
4
)
R
a
n
d
o
m
i
z
e
d
,
d
o
u
b
l
e
-
b
l
i
n
d
,
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
t
r
i
a
l
A
u
t
i
s
m
a
n
d
o
t
h
e
r
P
D
D
(
7
9
)
5
1
2
8
w
e
e
k
s
0
.
0
1
0
.
0
6
m
g
/
k
g
/
d
a
y
6
4
%
i
m
p
r
o
v
e
m
e
n
t
o
v
e
r
b
a
s
e
l
i
n
e
i
n
A
B
C
-
I
(
r
i
s
p
e
r
i
d
o
n
e
,
-
1
2
.
1
5
.
8
v
s
.
p
l
a
c
e
b
o
,
3
0
.
7
%
,
-
6
.
5
8
.
4
;
P
,
0
.
0
0
1
)
.
D
e
c
r
e
a
s
e
s
i
n
o
t
h
e
r
4
A
B
C
s
u
b
s
c
a
l
e
s
;
c
o
n
d
u
c
t
p
r
o
b
l
e
m
,
i
n
s
e
c
u
r
e
/
a
n
x
i
o
u
s
,
h
y
p
e
r
a
c
t
i
v
e
,
o
v
e
r
l
y
s
e
n
s
i
t
i
v
e
s
u
b
s
c
a
l
e
s
o
f
t
h
e
N
i
s
o
n
g
e
r
C
h
i
l
d
B
e
h
a
v
i
o
r
R
a
t
i
n
g
F
o
r
m
(
p
a
r
e
n
t
v
e
r
s
i
o
n
)
;
t
h
e
V
i
s
u
a
l
A
n
a
l
o
g
S
c
a
l
e
o
f
t
h
e
m
o
s
t
t
r
o
u
b
l
e
s
o
m
e
s
y
m
p
t
o
m
(
a
l
l
P
,
0
.
0
5
,
c
o
m
p
a
r
e
w
i
t
h
p
l
a
c
e
b
o
)
.
S
o
m
n
o
l
e
n
c
e
(
7
2
.
5
%
)
,
i
n
c
r
e
a
s
e
s
i
n
w
e
i
g
h
t
(
2
.
7
k
g
)
,
p
u
l
s
e
r
a
t
e
,
a
n
d
s
y
s
t
o
l
i
c
b
l
o
o
d
p
r
e
s
s
u
r
e
R
i
s
p
e
r
i
d
o
n
e
R
e
s
e
a
r
c
h
U
n
i
t
s
o
n
P
e
d
i
a
t
r
i
c
P
s
y
c
h
o
p
h
a
r
m
a
c
o
l
o
g
y
A
u
t
i
s
m
,
N
e
t
w
o
r
k
(
2
0
0
5
)
T
w
o
-
p
a
r
t
s
t
u
d
y
:
P
a
r
t
I
,
c
o
n
s
i
s
t
e
d
o
f
4
-
m
o
n
t
h
o
p
e
n
-
l
a
b
e
l
t
r
e
a
t
m
e
n
t
;
P
a
r
t
I
I
,
r
a
n
d
o
m
i
z
e
d
,
d
o
u
b
l
e
-
b
l
i
n
d
,
p
l
a
c
e
b
o
-
s
u
b
s
t
i
t
u
t
i
o
n
s
t
u
d
y
o
f
r
i
s
p
e
r
i
d
o
n
e
w
i
t
h
d
r
a
w
a
l
.
A
u
t
i
s
m
a
c
c
o
m
p
a
n
i
e
d
b
y
s
e
v
e
r
e
t
a
n
t
r
u
m
s
,
a
g
g
r
e
s
s
i
o
n
,
a
n
d
/
o
r
S
I
B
w
h
o
s
h
o
w
e
d
a
p
o
s
i
t
i
v
e
r
e
s
p
o
n
s
e
i
n
a
n
e
a
r
l
i
e
r
8
-
w
e
e
k
t
r
i
a
l
(
6
3
)
5
1
7
8
w
e
e
k
s
1
.
9
6
m
g
/
d
a
y
T
h
e
r
e
l
a
p
s
e
r
a
t
e
s
w
e
r
e
6
2
.
5
%
f
o
r
g
r
a
d
u
a
l
p
l
a
c
e
b
o
s
u
b
s
t
i
t
u
t
i
o
n
a
n
d
1
2
.
5
%
f
o
r
c
o
n
t
i
n
u
e
d
r
i
s
p
e
r
i
d
o
n
e
(
Y
a
t
e
s
s
c
o
r
r
e
c
t
e
d
2
=
6
.
5
3
,
d
f
=
1
,
P
=
0
.
0
1
)
R
i
s
p
e
r
i
d
o
n
e
M
c
D
o
u
g
l
e
e
t
a
l
.
(
2
0
0
5
)
D
o
u
b
l
e
-
b
l
i
n
d
,
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
t
r
i
a
l
A
u
t
i
s
m
(
1
0
1
)
5
1
7
8
w
e
e
k
s
G
r
e
a
t
e
r
r
e
d
u
c
t
i
o
n
i
n
t
h
e
o
v
e
r
a
l
l
i
n
R
F
R
L
R
S
,
s
u
b
s
c
a
l
e
s
f
o
r
s
e
n
s
o
r
y
m
o
t
o
r
b
e
h
a
v
i
o
r
s
,
a
f
f
e
c
t
u
a
l
r
e
a
c
t
i
o
n
s
,
a
n
d
s
e
n
s
o
r
y
r
e
s
p
o
n
s
e
s
.
G
r
e
a
t
e
r
r
e
d
u
c
t
i
o
n
s
i
n
s
c
o
r
e
s
o
n
C
Y
B
O
C
S
(
r
i
s
p
e
r
i
d
o
n
e
1
5
.
5
1
t
o
1
1
.
6
5
;
p
l
a
c
e
b
o
,
1
5
.
1
8
t
o
1
4
.
2
1
:
s
i
g
n
i
f
c
a
n
t
i
n
t
e
r
a
c
t
i
o
n
b
e
t
w
e
e
n
s
t
u
d
y
g
r
o
u
p
a
n
d
t
i
m
e
;
F
=
8
.
2
1
,
d
f
=
1
,
P
=
0
.
0
0
5
)
a
n
d
M
B
D
-
V
A
B
S
w
a
s
m
a
i
n
t
a
i
n
e
d
f
o
r
6
m
o
n
t
h
s
O
l
a
n
z
a
p
i
n
e
H
o
l
l
a
n
d
e
r
e
t
a
l
.
(
2
0
0
6
)
D
o
u
b
l
e
-
b
l
i
n
d
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
s
t
u
d
y
P
D
D
(
1
1
)
6
1
4
8
w
e
e
k
s
1
0
2
.
0
4
m
g
/
d
a
y
I
m
p
r
o
v
e
m
e
n
t
i
n
C
G
I
-
I
(
o
l
a
n
z
a
p
i
n
e
-
2
.
2
5
v
s
.
p
l
a
c
e
b
o
-
1
.
1
:
s
i
g
n
i
f
c
a
n
t
l
i
n
e
a
r
t
r
e
n
d
g
r
o
u
p
i
n
t
e
r
a
c
t
i
o
n
;
P
=
0
.
0
1
2
)
(
r
e
s
p
o
n
s
e
r
a
t
e
5
0
%
)
W
e
i
g
h
t
g
a
i
n
(
7
.
5
4
.
8
l
b
s
v
s
.
p
l
a
c
e
b
o
1
.
5
1
.
5
l
b
s
)
(
C
o
n
t
i
n
u
e
d
)
Kirino
24 CLINICAL MEDICINE INSIGHTS: PEDIATRICS 2014:8
T
a
b
l
e
1
.
(
C
o
n
t
i
n
u
e
d
)
A
g
E
n
T
R
E
f
E
R
E
n
C
E
S
T
u
d
Y
d
E
S
I
g
n
S
u
b
j
E
C
T
S
(
n
)
A
g
E
(
Y
E
A
R
S
)
d
u
R
A
T
I
O
n
d
O
S
A
g
E
C
l
I
n
I
C
A
l
O
u
T
C
O
m
E
S
T
O
l
E
R
A
b
I
l
I
T
Y
H
a
l
o
p
e
r
i
d
o
l
&
C
l
o
m
i
p
r
a
m
i
n
e
R
e
m
i
n
g
t
o
n
e
t
a
l
.
(
2
0
0
1
)
L
a
t
i
n
s
q
u
a
r
e
d
e
s
i
g
n
A
u
t
i
s
t
i
c
d
i
s
o
r
d
e
r
(
3
6
)
1
0
3
6
7
w
e
e
k
s
c
l
o
m
i
p
r
a
m
i
n
e
1
0
0
1
5
0
m
g
/
d
a
y
,
h
a
l
o
p
e
r
i
d
o
l
1
1
.
5
m
g
/
d
a
y
O
n
l
y
h
a
l
o
p
e
r
i
d
o
l
p
r
o
v
e
d
s
u
p
e
r
i
o
r
t
o
b
a
s
e
l
i
n
e
a
g
l
o
b
a
l
m
e
a
s
u
r
e
o
f
a
u
t
i
s
t
i
c
s
y
m
p
t
o
m
s
e
v
e
r
i
t
y
o
n
C
A
R
S
(
R
e
p
e
a
t
e
d
-
m
e
a
s
u
r
e
s
u
n
i
v
a
r
i
a
t
e
a
n
a
l
y
s
e
s
o
f
v
a
r
i
a
n
c
e
f
o
l
l
o
w
e
d
b
y
p
o
s
t
h
o
c
c
o
m
p
a
r
i
s
o
n
s
u
s
i
n
g
S
c
h
e
f
f
e
s
F
,
P
,
0
.
0
5
)
,
a
s
w
e
l
l
a
s
s
p
e
c
i
f
c
m
e
a
s
u
r
e
s
f
o
r
i
r
r
i
t
a
b
i
l
i
t
y
(
P
,
0
.
0
5
)
a
n
d
h
y
p
e
r
a
c
t
i
v
i
t
y
(
P
,
0
.
0
5
)
o
n
A
B
C
.
C
l
o
m
i
p
r
a
m
i
n
e
w
a
s
n
o
t
b
e
t
t
e
r
t
o
l
e
r
a
t
e
d
t
h
a
n
p
l
a
c
e
b
o
.
F
a
t
i
g
u
e
,
t
a
c
h
y
c
a
r
d
i
a
,
t
r
e
m
o
r
s
,
i
n
s
o
m
n
i
a
,
n
a
u
s
e
a
a
n
d
v
o
m
i
t
i
n
g
,
d
e
c
r
e
a
s
e
d
a
p
p
e
t
i
t
e
,
d
i
a
p
h
o
r
e
s
i
s
C
l
o
n
i
d
i
n
e
F
a
n
k
h
a
u
s
e
r
e
t
a
l
.
(
1
9
9
2
)
D
o
u
b
l
e
-
b
l
i
n
d
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
c
r
o
s
s
o
v
e
r
s
t
u
d
y
A
u
t
i
s
t
i
c
m
a
l
e
s
(
9
)
5
3
3
4
w
e
e
k
0
.
1
6
0
.
4
8
m
g
/
d
a
y
R
e
d
u
c
t
i
o
n
o
f
i
m
p
u
l
s
i
v
i
t
y
,
h
y
p
e
r
a
r
o
u
s
a
l
,
a
n
d
s
e
l
f
-
s
t
i
m
u
l
a
t
i
n
g
b
e
h
a
v
i
o
r
.
A
s
i
g
n
i
f
c
a
n
t
d
i
f
f
e
r
e
n
c
e
f
r
o
m
p
l
a
c
e
b
o
t
r
e
a
t
m
e
n
t
o
n
a
s
u
b
s
c
a
l
e
(
s
e
n
s
o
r
y
r
e
s
p
o
n
s
e
s
)
o
f
t
h
e
R
i
t
v
o
-
F
r
e
e
m
a
n
R
e
a
l
L
i
f
e
R
a
t
i
n
g
S
c
a
l
e
(
a
n
a
l
y
s
e
s
o
f
v
a
r
i
a
n
c
e
:
P
,
0
.
0
5
)
,
t
h
e
C
G
I
-
I
(
P
,
0
.
0
0
0
1
)
a
n
d
t
h
e
t
h
e
r
a
p
e
u
t
i
c
e
f
f
e
c
t
i
t
e
m
o
f
C
G
I
(
P
=
0
.
0
0
0
3
)
.
S
e
d
a
t
i
o
n
,
h
y
p
o
t
e
n
s
i
o
n
,
f
a
t
i
g
u
e
,
d
e
c
r
e
a
s
e
d
a
c
t
i
v
i
t
y
G
u
a
n
f
a
c
i
n
e
H
a
n
d
e
n
e
t
a
l
.
(
2
0
0
8
)
D
o
u
b
l
e
-
b
l
i
n
d
,
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
c
r
o
s
s
o
v
e
r
t
r
i
a
l
A
u
t
i
s
m
a
n
d
/
o
r
i
n
t
e
l
l
e
c
t
u
a
l
d
i
s
a
b
i
l
i
t
i
e
s
(
1
1
)
5
9
6
w
e
e
k
s
3
m
g
4
5
%
o
f
c
h
i
l
d
r
e
n
h
a
d
a
5
0
%
r
e
d
u
c
t
i
o
n
i
n
t
h
e
A
B
C
h
y
p
e
r
a
c
t
i
v
i
t
y
.
T
h
e
C
G
I
-
I
(
I
n
d
e
p
e
n
d
e
n
t
-
s
a
m
p
l
e
t
-
t
e
s
t
:
P
=
0
.
0
0
5
)
,
P
a
r
e
n
t
A
B
C
H
y
p
e
r
a
c
t
i
v
i
t
y
s
u
b
s
c
a
l
e
(
P
=
0
.
0
2
5
)
,
a
n
d
T
e
a
c
h
e
r
A
B
C
H
y
p
e
r
a
c
t
i
v
i
t
y
s
u
b
s
c
a
l
e
(
P
=
0
.
0
0
5
)
w
e
r
e
f
o
u
n
d
t
o
h
a
v
e
s
t
a
t
i
s
t
i
c
a
l
l
y
s
i
g
n
i
f
c
a
n
t
d
i
f
f
e
r
e
n
c
e
s
b
e
t
w
e
e
n
g
u
a
n
f
a
c
i
n
e
a
n
d
p
l
a
c
e
b
o
g
r
o
u
p
s
.
S
e
d
a
t
i
o
n
,
i
r
r
i
t
a
b
i
l
i
t
y
L
a
m
o
t
r
i
g
i
n
e
B
e
l
s
i
t
o
e
t
a
l
.
(
2
0
0
1
)
D
o
u
b
l
e
-
b
l
i
n
d
,
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
,
p
a
r
a
l
l
e
l
g
r
o
u
p
s
t
u
d
y
A
u
t
i
s
m
(
2
8
)
3
1
1
1
8
w
e
e
k
s
5
.
0
m
g
/
k
g
/
d
a
y
N
o
s
i
g
n
i
f
c
a
n
t
d
i
f
f
e
r
e
n
c
e
s
i
n
i
m
p
r
o
v
e
m
e
n
t
s
b
e
t
w
e
e
n
l
a
m
o
t
r
i
g
i
n
e
o
r
p
l
a
c
e
b
o
o
n
t
h
e
A
u
t
i
s
m
B
e
h
a
v
i
o
r
C
h
e
c
k
l
i
s
t
,
t
h
e
A
B
C
,
t
h
e
P
L
-
A
D
O
S
,
V
i
n
e
l
a
n
d
A
d
a
p
t
i
v
e
B
e
h
a
v
i
o
r
s
c
a
l
e
s
o
r
t
h
e
C
A
R
S
.
(
R
e
p
e
a
t
e
d
m
e
a
s
u
r
e
s
a
n
a
l
y
s
i
s
o
f
v
a
r
i
a
n
c
e
s
)
I
n
s
o
m
n
i
a
,
h
y
p
e
r
a
c
t
i
v
i
t
y
Pharmacotherapy for the treatment of irritability in autistic children
25 CLINICAL MEDICINE INSIGHTS: PEDIATRICS 2014:8
L
e
v
e
t
i
r
a
c
e
t
a
m
W
a
s
s
e
r
m
a
n
e
t
a
l
.
(
2
0
0
6
)
D
o
u
b
l
e
-
b
l
i
n
d
,
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
t
r
i
a
l
A
u
t
i
s
m
(
2
0
)
5
1
7
1
0
w
e
e
k
s
8
6
2
.
5
2
7
9
.
1
9
m
g
N
o
d
i
f
f
e
r
e
n
c
e
b
e
t
w
e
e
n
d
r
u
g
a
n
d
p
l
a
c
e
b
o
i
n
C
G
I
-
I
(
t
=
0
.
3
5
0
,
d
f
=
1
3
.
6
2
1
,
P
=
0
.
7
6
5
)
,
n
o
r
i
n
t
h
e
m
o
o
d
a
n
d
t
h
e
i
r
r
i
t
a
b
i
l
i
t
y
s
c
a
l
e
s
o
n
t
h
e
A
B
C
,
C
Y
-
B
O
C
S
o
r
C
o
n
n
e
r
s
'
s
c
a
l
e
s
.
A
g
i
t
a
t
i
o
n
,
a
g
g
r
e
s
s
i
o
n
M
e
t
h
y
l
p
h
e
n
i
d
a
t
e
Q
u
i
n
t
a
n
a
e
t
a
l
.
(
1
9
9
5
)
D
o
u
b
l
e
-
b
l
i
n
d
c
r
o
s
s
o
v
e
r
s
t
u
d
y
A
u
t
i
s
t
i
c
d
i
s
o
r
d
e
r
(
1
0
)
7
1
1
2
w
e
e
k
s
2
0
o
r
4
0
m
g
/
d
a
y
S
i
g
n
i
f
c
a
n
t
r
e
d
u
c
t
i
o
n
i
n
t
h
e
C
o
n
n
e
r
s
T
e
a
c
h
e
r
Q
u
e
s
t
i
o
n
n
a
i
r
e
(
M
e
t
h
y
l
p
h
e
n
i
d
a
t
e
1
.
3
0
.
7
v
s
.
p
l
a
c
e
b
o
1
.
5
0
.
3
,
t
=
2
.
6
9
,
P
=
.
0
2
)
,
A
B
C
-
t
o
t
a
l
(
4
2
.
0
1
8
.
3
v
s
.
5
2
.
4
2
2
.
5
,
t
=
2
.
4
3
,
P
=
.
0
4
)
,
A
B
C
-
I
(
4
.
0
3
.
8
v
s
.
7
.
2
6
.
3
,
t
=
3
.
2
3
,
P
=
.
0
1
)
,
a
n
d
A
B
C
-
h
y
p
e
r
a
c
t
i
v
i
t
y
(
1
2
.
1
9
.
4
v
s
.
1
9
.
8
1
7
.
9
,
t
=
2
.
8
2
,
P
=
.
0
2
)
,
a
s
c
o
m
p
a
r
e
d
t
o
p
l
a
c
e
b
o
.
d
e
c
r
e
a
s
e
d
a
p
p
e
t
i
t
e
,
i
r
r
i
t
a
b
i
l
i
t
y
,
i
n
s
o
m
n
i
a
,
s
t
o
m
a
c
h
a
c
h
e
,
h
e
a
d
a
c
h
e
M
e
t
h
y
l
p
h
e
n
i
d
a
t
e
H
a
n
d
e
n
e
t
a
l
.
(
2
0
0
0
)
D
o
u
b
l
e
-
b
l
i
n
d
,
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
,
c
r
o
s
s
o
v
e
r
d
e
s
i
g
n
A
u
t
i
s
m
o
r
P
D
D
-
N
O
S
w
i
t
h
s
y
m
p
t
o
m
s
o
f
A
D
H
D
(
1
3
)
5
.
6
1
1
.
2
o
v
e
r
7
d
a
y
s
0
.
3
o
r
0
.
6
m
g
/
k
g
S
i
g
n
i
f
c
a
n
t
i
m
p
r
o
v
e
m
e
n
t
o
n
t
h
e
H
y
p
e
r
a
c
t
i
v
i
t
y
I
n
d
e
x
o
f
t
h
e
C
o
n
n
e
r
s
(
R
e
p
e
a
t
e
d
-
m
e
a
s
u
r
e
s
a
n
a
l
y
s
e
s
o
f
v
a
r
i
a
n
c
e
f
o
l
l
o
w
e
d
b
y
p
o
s
t
h
o
c
c
o
m
p
a
r
i
s
o
n
s
:
P
,
0
.
0
0
1
)
,
I
O
W
A
C
o
n
n
e
r
s
T
e
a
c
h
e
r
R
a
t
i
n
g
S
c
a
l
e
(
P
=
0
.
0
0
4
)
,
a
n
d
H
y
p
e
r
a
c
t
i
v
i
t
y
(
P
=
0
.
0
0
3
)
a
n
d
I
n
a
p
p
r
o
p
r
i
a
t
e
S
p
e
e
c
h
(
P
=
0
.
0
0
1
)
o
n
A
B
C
,
a
s
c
o
m
p
a
r
e
d
t
o
p
l
a
c
e
b
o
.
S
o
c
i
a
l
w
i
t
h
d
r
a
w
a
l
,
d
u
l
l
n
e
s
s
,
s
a
d
n
e
s
s
,
i
r
r
i
t
a
b
i
l
i
t
y
,
s
k
i
n
p
i
c
k
i
n
g
.
A
m
a
n
t
a
d
i
n
e
K
i
n
g
e
t
a
l
.
(
2
0
0
1
)
D
o
u
b
l
e
-
b
l
i
n
d
,
p
l
a
c
e
b
o
c
o
n
t
r
o
l
l
e
d
A
u
t
i
s
m
(
3
9
)
5
1
9
5
w
e
e
k
s
5
.
0
m
g
/
k
g
/
d
a
y
N
o
d
i
f
f
e
r
e
n
c
e
s
b
e
t
w
e
e
n
g
r
o
u
p
s
p
a
r
e
n
t
-
r
a
t
e
d
A
B
C
-
C
V
.
S
i
g
n
i
f
c
a
n
t
i
m
p
r
o
v
e
m
e
n
t
s
i
n
a
b
s
o
l
u
t
e
c
h
a
n
g
e
s
i
n
c
l
i
n
i
c
i
a
n
-
r
a
t
e
d
A
B
C
-
C
V
s
f
o
r
h
y
p
e
r
a
c
t
i
v
i
t
y
(
a
m
a
n
t
a
d
i
n
e
-
6
.
4
v
e
r
s
u
s
p
l
a
c
e
b
o
-
2
.
1
;
P
=
.
0
4
6
)
a
n
d
i
n
a
p
p
r
o
p
r
i
a
t
e
s
p
e
e
c
h
(
-
1
.
9
v
e
r
s
u
s
0
.
4
;
P
=
.
0
0
8
)
.
H
i
g
h
e
r
C
G
I
s
c
a
l
e
r
a
t
i
n
g
s
(
5
3
%
i
m
p
r
o
v
e
d
v
e
r
s
u
s
2
5
%
:
P
=
.
0
7
6
)
.
I
n
s
o
m
n
i
a
,
s
o
m
n
o
l
e
n
c
e
L
-
c
a
r
n
i
t
i
n
e
G
e
i
e
r
e
t
a
l
.
(
2
0
1
1
)
R
a
n
d
o
m
i
z
e
d
c
o
n
t
r
o
l
l
e
d
t
r
i
a
l
A
S
D
(
3
0
)
3
1
0
3
m
o
n
t
h
5
0
m
g
/
k
g
/
d
a
y
S
i
g
n
i
f
c
a
n
t
R
e
d
u
c
t
i
o
n
i
n
C
A
R
S
(
c
o
n
t
r
a
s
t
b
e
t
w
e
e
n
g
r
o
u
p
s
:
-
2
.
0
3
,
9
5
%
C
I
=
3
.
7
t
o
0
.
3
1
;
P
=
0
.
0
2
)
s
c
o
r
e
a
n
d
m
o
d
i
f
e
d
C
G
I
-
I
(
-
0
.
6
9
,
9
5
%
C
I
=
1
.
1
t
o
0
.
0
6
;
P
=
0
.
0
3
)
.
W
e
l
l
t
o
l
e
r
a
t
e
d
w
i
t
h
a
d
v
e
r
s
e
e
f
f
e
c
t
s
o
f
i
r
r
i
t
a
b
i
l
i
t
y
,
s
t
o
m
a
c
h
d
i
s
c
o
m
f
o
r
t
Kirino
26 CLINICAL MEDICINE INSIGHTS: PEDIATRICS 2014:8
Weight gain, metabolic consequences. Aripiprazole
causes less weight gain because it has a low afnity for his-
tamine H1 receptors, and it is a partial agonist of serotonin
5-HT2C receptors, which are associated with weight gain and
obesity.
27,28,78
Additionally, because of the low afnity for the
histamine H1 receptors, the incidence of oversedation is low.
78
Furthermore, aripiprazole has almost no afnity for muscar-
inic M1 receptors, so it has few anticholinergic efects, such as
constipation, dry mouth, urinary retention, or efects on cog-
nitive function.
79
In the nonrandomized Second-Generation
Antipsychotic Treatment Indications, Efectiveness and
Tolerability in Youth (SATIETY) cohort study, Correll
et al.
79
evaluated the efects of olanzapine, quetiapine, risperi-
done, and aripiprazole on body composition and metabolic
parameters in 338 pediatric and adolescent patients who were
treated for 12 weeks without prior antipsychotic medication
exposure. Te patients weight increased signifcantly in the
antipsychotic treatment groups; aripiprazole caused the least
amount of weight gain. Furthermore, serum total cholesterol,
triglycerides, and nonhigh-density lipoprotein cholesterol
(total cholesterol minus high-density lipoprotein cholesterol)
increased signifcantly with olanzapine, quetiapine, and ris-
peridone, but not with aripiprazole.
79
On the other hand, in a long-term, placebo-controlled
trial conducted with autistic children by Findling et al.
52
arip-
iorazole patients gained an average of 1.6 kg of weight gain,
which was more than the weight gained by placebo recipients.
Terefore, careful monitoring of weight should be performed
over the course of treatment with aripiprazole, although arip-
iprazole causes less weight gain in comparison with other
atypical antipsychotics.
Risperidone. In a pooled descriptive analysis of short-term
clinical trials,
38
the most common treatment-emergent adverse
events (ie, those occurring in .1.0% of patients receiving ris-
peridone [n = 76] and at a rate that was at least twice that in
the placebo group [n = 80]) were somnolence, increased appe-
tite, fatigue, upper respiratory tract infection, increased saliva,
constipation, dry mouth, tremor, and dystonia. Te most com-
mon of these was somnolence, which was generally transient
in nature.
38
EPS. Tere was a higher incidence of adverse events
associated with EPS in the risperidone group than in the
placebo group in a pooled analysis of short-term trials evalu-
ating risperidone treatment.
38
In clinical trials, tardive dys-
kinesia occurred in two of 1,885 children and adolescents
with autistic disorder or other psychiatric disorders receiving
risperidone, with these cases resolving upon discontinuation
of treatment.
38
Serum prolactin. Eight children (28%) of 25 young autis-
tic children (22 males and three females; age range, 3.97
years; mean age, 4.10 years) during treatment with risperidone
(dosage range: 0.250.90 mg/day; mean dosage 0.52 mg/day)
had prolactin levels (30 ng/mL) higher than two times the
upper limit after 10 weeks of treatment.
80
In double-blind
trials, 49% of children and adolescents receiving risperidone
had elevated serum prolactin levels, while 2% of patients did
in the placebo group.
38,81
Monitoring of prolactin during
treatment with risperidone may be warranted.
80
Weight gain and growth/sexual maturation. Risperi-
done treatment was associated with weight gain in short- and
longer-term trials,
53,56
with these increases being in excess of
developmentally expected norms, and which follow a curvi-
linear trajectory and decelerate over time.
82
Tere was no cor-
relation between serum leptin levels and weight gain in 63
children and adolescents with autistic disorder receiving ris-
peridone for up to 6 months. Serum leptin change does not
reliably predict risperidone-associated weight gain.
82
Te long-term efects of risperidone on growth and sexual
maturation remain to be fully evaluated.
36,38
In a retrospec-
tive analysis of pooled data from fve clinical trials conducted
with 572 evaluable children (aged 515 years) with disruptive
behavior disorders receiving risperidone for up to 1 year, there
were no statistically signifcant or clinically relevant efects on
growth, or on the onset or progression of puberty.
38
Olanzapine. Common adverse events included seda-
tion and weight gain.
6
Rhinitis, glazed eyes, constipation,
and insomnia were also reported.
58
Although olanzapine is a
potentially efective treatment for irritability in autism because
the risk of adverse events, including EPS, appears to be low,
the increase in weight and appetite associated with olanzapine
use may well be a limiting factor in its use and in its investiga-
tion for use in ASD.
58,8388
Typical antipsychotics (haloperidol). Te most commonly
reported adverse events were constipation, blunted afect,
rigidity, dystonia, insomnia, increased appetite, depression,
fatigue, and upper respiratory tract infection.
6,89
A study by
Perry et al.
62
enrolled 60 children (age range, 2.37.9 years)
with autism who were responders to haloperidol. Te sub-
jects were randomized to continuous or discontinuous (5 days
on and 2 days of) treatment with haloperidol for 6 months,
after which they all received 4 weeks of placebo. Although
all were reversible, three youth developed dyskinesias during
haloperidol treatment and nine developed withdrawal dyski-
nesias during the placebo period.
62
Another study by Camp-
bell et al.
63
prospectively monitored the emergence of tardive
dyskinesia and withdrawal dyskinesia in 118 children with
autism aged 2.38.2 years. Te youth received 6 months of
haloperidol followed by 1 month of placebo, after which the
need for another cycle of haloperidol treatment followed by
placebo was assessed. In this study, 40 of 118 (33.9%) subjects
developed dyskinesias, primarily reversible withdrawal dyski-
nesias. Of the individuals on a higher mean dosage (3.4 mg/
day) of haloperidol during the study, nine of ten (90%) devel-
oped dyskinesias.
63
Clomipramine. In one RCT, clomipramine was not bet-
ter tolerated than placebo.
64
Te adverse events included
fatigue, tachycardia, tremors, insomnia, nausea and vomiting,
decreased appetite, and diaphoresis.
64
Pharmacotherapy for the treatment of irritability in autistic children
27 CLINICAL MEDICINE INSIGHTS: PEDIATRICS 2014:8
-2 adrenergic agonists. Clonidine. Te side efects noted
in the two clonidine trials included sedation, hypotension,
fatigue, and decreased activity.
65,90
Guanfacine. Te side efects noted in the two guanfacine
trials were sedation and irritability.
66,91
Antiepileptic drugs. Lamotrigine. In one study, the most
notable side efects were insomnia and hyperactivity, at a fnal
dose of 5 mg/kg per day. None of the children enrolled in the
trial were withdrawn due to skin rash (a potentially serious
adverse efect of lamotrigine treatment).
67
Psychostimulants (methylphenidate). In one RCT,
adverse efects of decreased appetite, irritability, insomnia,
stomachache, and headache were reported.
69
In another RCT,
fve of 13 children experienced severe side efects, including
social withdrawal, dullness, sadness, irritability, and skin
picking. Tese side efects caused three subjects to be discon-
tinued from the study.
70
Antiparkinsonian medication (amantadine). In the RCT,
patients reported adverse efects of insomnia and somnolence
more often.
71
Carnitine (L-carnitine). In the RCT, L-carnitine was
generally well tolerated, with adverse efects of irritability and
stomach discomfort.
72
Place in therapy. Aripiprazole. Greenaway and Elbe
31
concluded in their review that in children and adolescents,
aripiprazole appears to have minimal impact on the patients
metabolic profle compared to most other atypical antipsychot-
ics, and that aripiprazole may represent an important alterna-
tive for some children and adolescents who have experienced
poor efcacy or signifcant metabolic adverse efects with their
current antipsychotic treatment regimen.
31
Teir arguments
are reconciled with other reports in that aripiprazole is gener-
ally safe and well tolerated in the treatment of irritability in
autistic disorders.
9,10,9295
Aripiprazole also improves qualita-
tive disorders in interpersonal interactions, including commu-
nication skills and motivation.
94,95
In summary, compared with other antipsychotics, arip-
iprazole causes fewer adverse events that can lead to drug dis-
continuation (for example, EPS, weight gain, and sedation).
Terefore, aripiprazole is associated with excellent treatment
compliance and is a promising drug to improve treatment out-
comes in ASDs.
Risperidone. Risperidone had a clinically manageable
tolerability profle, with most adverse events being of mild to
moderate intensity. Tere are some aspects of treatment, such
as weight gain, somnolence, hyperprolactinemia, hypergly-
cemia, and EPS that require monitoring, and the long-term
safety of risperidone in children with autistic disorder remains
to be fully determined.
36,37
Olanzapine. Although olanzapine may be a promising
treatment that is well tolerated for the treatment of some behav-
ioral symptoms (irritability, hyperactivity/noncompliance, and
lethargy/withdrawal) associated with ASDs, the risk of sig-
nifcant weight gain remains a concern.
58,8388
Te non-RCT
or short period trial limits the ability to make inferences about
common side efects such as weight gain, lipidemia, and tar-
dive dyskinesia. Further long-term RCTs of olanzapine are
required.
Clozapine. Te dearth of reports on the use of clozapine in
ASDs is most likely due to its potential to cause life-threatening
agranulocytosis, as well as its propensity to lower the seizure
threshold. Frequent blood draws and cardiovascular monitor-
ing, which are difcult procedures for children with autism,
also make this atypical antipsychotic a less than ideal candi-
date.
96
Patients with an impaired ability to communicate and
those with cognitive impairments would likely encounter dif-
fculty tolerating weekly to biweekly venipuncture to monitor
white blood cell counts.
97
Typical antipsychotics (haloperidol). Although potentially
benefcial, the current role of haloperidol is limited to treat-
ment-refractory patients due to concerns regarding its associ-
ated adverse efects, including frequently observed EPS.
13
-2 adrenergic agonists. Although clonidine and guanfacine
are well tolerated in RCTs,
65,66
the efcacy and long-term safety
for the irritability of autism remains to be fully determined.
Antiepileptic drugs. Due to the fnding of increased
insomnia and hyperactivity,
67
lamotrigine is not a frst-line
agent to control irritable and aggressive symptoms in a popu-
lation of children who frequently complain of insomnia and
hyperactivity.
96
Te fndings of increased aggression
68,98
make
levetiracetam a fnal option in the treatment of children with
autism, unless the child has refractory epilepsy.
96
Psychostimulants (methylphenidate). Te two RCTs
69,70
produced signifcant results, but their sample sizes were small
and the study duration was relatively short.
11
Antiparkinsonian medication (amantadine). In the RCT
of King et al.
71
clinician-rated improvements were noted in
behavioral ratings following treatment with amantadine;
however, parents did not report statistically signifcant behav-
ioral changes with amantadine.
Carnitine (L-carnitine). L-carnitine was proposed as
a potential treatment for patients diagnosed with ASD to
improve mitochondrial dysfunction. L-carnitine therapy
administered for 3 months signifcantly improved several
clinical measurements of ASD severity, but subsequent stud-
ies are recommended.
72
Clomipramine. In the RCT, clomipramine did not seem
to be more efective, nor was it better tolerated in comparison
with haloperidol or placebo.
64
Limitations
Tis study has some limitations. First, RCTs investigat-
ing the efcacy and tolerability of pharmacotherapy for the
treatment of irritability in autistic children are still limited.
Conclusions drawn from such studies must be evaluated
with caution, and further accumulation of controlled stud-
ies is needed. Second, studies evaluating the long-term con-
sequences of treatment are limited. Further investigations
Kirino
28 CLINICAL MEDICINE INSIGHTS: PEDIATRICS 2014:8
will provide the answers to these problems, which are
fundamental for clinicians.
Conclusion
Tis paper reviewed the pharmacological profle and outcomes
of previous clinical studies of pharmacotherapy for the treat-
ment of irritability in autistic children. Te four risperidone
RCTs and the two aripiprazole RCTs reported statistically
signifcant improvements in primary outcome measures. Tus,
the bulk of positive RCT evidence regarding the pharmaco-
therapy treatment of irritability in autism pertains to the FDA-
approved antipsychotics risperidone and aripiprazole. RCTs
supporting the efcacy of several alternative and adjunctive
agents may aford additional treatment options when optimal
antipsychotic doses fail to control symptoms or cause intolerable
adverse efects.
6
Among atypical antipsychotics, olanzapine
58,8587
and
quetiapine
99101
are limited in their use for ASDs among
children because of the drugs high incidences of weight
gain and sedation. In comparison, aripiprazole
79,102,103
and
ziprasidone
104,105
cause less weight gain and sedation, although
there was no obvious trend in favor of aripiprazole regarding
weight gain in a long-term observation study,
52
and no RCTs
have been conducted regarding the use of ziprasidone among
autistic children. Furthermore, the potential QTc interval pro-
longation with ziprasidone has been reported.
7577
Contrary to
ziprasidone, no changes were evident in the QT interval in
any trials for aripiprazole.
9,10,73
However, head-to-head com-
parison studies are needed to support the idea that aripiprazole
may be a promising drug that can be used to treat irritability
in autistic children. On the other hand, risperidone has the
greatest amount of evidence to support it (including RCTs);
thus, its efcacy and tolerability have been established in com-
parison with other agents. Further studies with risperidone as
a control drug are thus needed.
Author Contributions
Conceived the concept: EK. Analyzed the data: EK. Wrote
the frst draft of the manuscript: EK. Made critical revi-
sions: EK. Te author reviewed and approved of the fnal
manuscript.
REFERENCES
1. Wink LK, Erickson CA, McDougle CJ. Pharmacologic treatment of behavioral
symptoms associated with autism and other pervasive developmental disorders.
Curr Treat Options Neurol. 2010;12(6):52938.
2. Stachnik JM, Nunn-Tompson C. Use of atypical antipsychotics in the treat-
ment of autistic disorder. Ann Pharmacother. 2007;41(4):62634.
3. Lounds Taylor J, Dove D, Veenstra-VanderWeele J, et al. AHRQ compara-
tive efectiveness reviews. In: Interventions for Adolescents and Young Adults with
Autism Spectrum Disorders. Rockville, MD: Agency for Healthcare Research and
Quality (US); 2012.
4. Chou R, Aronson N, Atkins D, et al. AHRQ series paper 4: assessing harms
when comparing medical interventions: AHRQ and the efective health-care
program. J Clin Epidemiol. 2010;63(5):50212.
5. Reichow B, Steiner AM, Volkmar F. Cochrane review: social skills groups for
people aged 6 to 21 with autism spectrum disorders (ASD). Evid Based Child
Health. 2013;8(2):266315.
6. Elbe D, Lalani Z. Review of the pharmacotherapy of irritability of autism. J Can
Acad Child Adolesc Psychiatry. 2012;21(2):13046.
7. Lecavalier L. Behavioral and emotional problems in young people with pervasive
developmental disorders: relative prevalence, efects of subject characteristics,
and empirical classifcation. J Autism Dev Disord. 2006;36(8):110114.
8. Horner RH, Carr EG, Strain PS, Todd AW, Reed HK. Problem behavior inter-
ventions for young children with autism: a research synthesis. J Autism Dev Dis-
ord. 2002;32(5):42346.
9. Marcus RN, Owen R, Kamen L, et al. A placebo-controlled, fxed-dose study of
aripiprazole in children and adolescents with irritability associated with autistic
disorder. J Am Acad Child Adolesc Psychiatry. 2009;48(11):11109.
10. Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of
irritability in children and adolescents with autistic disorder. Pediatrics.
2009;124(6):153340.
11. Parikh MS, Kolevzon A, Hollander E. Psychopharmacology of aggression in
children and adolescents with autism: a critical review of efcacy and tolerability.
J Child Adolesc Psychopharmacol. 2008;18(2):15778.
12. McDougle CJ, Posey DJ, Stigler KA. Pharmacological treatments. In: Moldin SO,
Rubenstein JLR, editors. Understanding Autism: From Basic Neuroscience to
Treatment. Boca Raton, FL: CRC Press; 2006:41742.
13. Stigler KA, McDougle CJ. Pharmacotherapy of irritability in pervasive develop-
mental disorders. Child Adolesc Psychiatr Clin N Am. 2008;17(4):73952, viiviii.
14. Hollander E, Phillips AT, Yeh CC. Targeted treatments for symptom domains
in child and adolescent autism. Lancet. 2003;362(9385):73234.
15. Blankenship K, Erickson CA, Stigler KA, Posey DJ, McDougle CJ. Aripipra-
zole for irritability associated with autistic disorder in children and adolescents
aged 617 years. Ped Health. 2010;4(4):37581.
16. Llorca PM, Chereau I, Bayle FJ, Lancon C. Tardive dyskinesias and antipsy-
chotics: a review. Eur Psychiatry. 2002;17(3):12938.
17. Janciak PG, Marder SR, Pavuluri MN. Principles and Practice of Psychopharmaco-
therapy. Philadelphia, PA: Lippincott Williams & Wilkins; 2001.
18. Chavez B, Chavez-Brown M, Sopko MA Jr, Rey JA. Atypical antipsychotics in chil-
dren with pervasive developmental disorders. Paediatr Drugs. 2007;9(4):24966.
19. Anderson GM. Genetics of childhood disorders: XLV. Autism, part 4: serotonin
in autism. J Am Acad Child Adolesc Psychiatry. 2002;41(12):151316.
20. Cook EH. Autism: review of neurochemical investigation. Synapse. 1990;6(3):
292308.
21. Anderson GM, Freedman DX, Cohen DJ, et al. Whole blood serotonin in autis-
tic and normal subjects. J Child Psychol Psychiatry. 1987;28(6):885900.
22. Palermo MT, Curatolo P. Pharmacologic treatment of autism. J Child Neurol.
2004;19(3):15564.
23. Kikuchi T. Te research and development of aripiprazole and its mechanism of
action. Japanese Journal of Clinical Psychopharmacology. 2007;10(3):4648.
24. Stahl SM, Shayegan DK. Te psychopharmacology of ziprasidone: receptor-
binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64
Suppl 19:612.
25. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation
of antipsychotics, part 1, Goldilocks actions at dopamine receptors. J Clin Psy-
chiatry. 2001;62(11):8412.
26. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of
antipsychotics, part 2: illustrating their mechanism of action. J Clin Psychiatry.
2001;62(12):9234.
27. DeBattista C, Hawkins J. Utility of atypical antipsychotics in the treatment of
resistant unipolar depression. CNS Drugs. 2009;23(5):36977.
28. Fernandez HH, Trieschmann ME, Friedman JH. Aripiprazole for drug-induced
psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol.
2004;27(1):45.
29. Hirose T, Uwahodo Y, Yamada S, et al. Mechanism of action of aripiprazole
predicts clinical efcacy and a favourable side-efect profle. J Psychopharmacol.
2004;18(3):37583.
30. Findling RL, Blumer JL, Kaufman R, et al. Pharmacokinetic efects of aripip-
razole in children and adolescents with conduct disorder. Paper presented at: the
XXIVth Collegium Internationale Neuro-Psychopharmacologicum Congress;
June 204, 2004; Paris, France.
31. Greenaway M, Elbe D. Focus on aripiprazole: a review of its use in child and
adolescent psychiatry. J Can Acad Child Adolesc Psychiatry. 2009;18(3):25060.
32. Otsuka Pharmaceutial Co. Abilify